Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Penicillin-binding protein 4 (PBP4) is a low-affinity, class B transpeptidase involved in bacterial cell wall biosynthesis. It catalyzes the cross-linking of peptidoglycan chains, providing structural integrity to the bacterial cell wall. PBP4 contributes to β-lactam antibiotic resistance in certain bacteria, such as Enterococcus faecalis and Staphylococcus aureus, by maintaining transpeptidase activity even when other PBPs are inhibited. It contains a conserved active site with a catalytic serine residue that is acylated by β-lactam antibiotics, leading to inactivation. However, due to its low affinity, PBP4 can contribute to resistance.
β-lactam antibiotics inhibit PBP4 by acylating the active site serine residue, preventing peptidoglycan cross-linking.
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Penicillin-binding protein 4 (PBP4).